minoxidil + finasteride (EMS)

A combination therapy consisting of topical minoxidil and oral finasteride, utilized by the pharmaceutical company EMS as an active comparator in Phase 3 clinical trials (such as NCT04594018) for the treatment of androgenetic alopecia. Minoxidil is a vasodilator that promotes hair growth by potentially opening ATP-sensitive potassium channels and increasing blood flow to hair follicles, which may prolong the anagen phase of the hair cycle. Finasteride is a 5α-reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT), the primary androgen responsible for hair follicle miniaturization in male pattern baldness. In clinical studies conducted by EMS, this combination serves as the standard-of-care reference for evaluating the efficacy and safety of new hair loss treatments like the Finlândia hair lotion association.

Other names

minoxidil + finasteride-EMS-androgenetic alopeciaMinoxidil hair lotion + Finasteride 1 mg